Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer
about
Immunological Landscape and Clinical Management of Rectal CancerMTHFR C677T Polymorphism is Associated with Tumor Response to Preoperative Chemoradiotherapy: A Result Based on Previous ReportsGenetic and epigenetic traits as biomarkers in colorectal cancerGene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancerTP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cellsComparative analysis of radiosensitizers for K-RAS mutant rectal cancersMutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinomaThe molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer?KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer.Intra-tumor genetic heterogeneity in rectal cancerComparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.An 80-gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysisThe status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation.Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy.Is Pathologic Near-Total Regression an Appropriate Indicator of a Good Response to Preoperative Chemoradiotherapy Based on Oncologic Outcome of Disease?Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.Effect of Neoadjuvant Chemoradiotherapy on Locally Advanced Rectal Mucinous Adenocarcinoma: A Propensity Score-Matched Study.Minimal access surgery for rectal cancer: an update.Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer.Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.Progress in rectal cancer treatment.KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinomaModern Treatment of Rectal Cancer Closes the Gap Between Common Adenocarcinoma and Mucinous Carcinoma.Predictive clinical model of tumor response after chemoradiation in rectal cancer.Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial.Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation.High Ran level is correlated with poor prognosis in patients with colorectal cancer.Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes.KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy?Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging.
P2860
Q26768531-5DC781C3-29C0-458D-B79A-7D33D18C8AEDQ26784493-6CF78A6F-5102-4E88-9D60-D566C2FC1CF5Q27016019-ACF8E4F3-2CF1-4392-9236-A61199CF3415Q28392548-5B9EC33F-97BF-4A45-ABE4-DDE53681F5FCQ34926012-B4ADA4D3-ECDE-42A7-BB30-3F70BD54B49CQ35070685-AFB7AC99-148F-4E6E-883F-6BFB9D2D285CQ35183160-30E7DA28-6391-4CBC-B2E3-C709216E982AQ35832569-A2F7CEF9-9A34-4652-A282-4D2CC856D308Q35859128-4981653A-AFBA-4153-B719-FDED16DD46BFQ36014263-28C326AD-29AE-42E1-8851-D4777AFFC34FQ36194689-EAAA7FE6-5336-4A6C-8137-53757464FE2EQ36358764-748A4F4B-E863-47F9-8585-51FB8EB24EB9Q36414682-A609CEBC-02AF-4819-A79F-21DAFB60692BQ36540452-DAC3CEF8-909B-4B87-9B8E-A39B2F8D02A2Q36824711-236CD2E3-37D7-476B-920B-62E0FACCA571Q37015715-003276A3-0E2F-4E5E-8977-5C318FF25FF7Q37205031-22249012-BD76-48F9-9B9A-8883437B208BQ37323833-C1050AF8-E913-4B2D-A828-259BA3873E73Q37328335-EDFB0085-1366-4BB9-86F0-90BD6B6FD613Q37729169-9B7E51BE-E6AD-410B-925A-F808DDCA5AEBQ37733511-C8F2FAC3-0F87-4B2D-9D29-BE302769C069Q38160142-2407E4E1-DB85-45E1-BC49-08C71DFF7F4FQ38288716-A18455BC-4319-45A0-A2EA-1528BE10D20DQ38367771-8B63DD35-4A71-4189-9F77-88A0B636EEA6Q38539917-5A7C2BFE-402F-478D-B0FE-8FD9EEA01164Q38623990-0D4BD213-5B87-4B58-A928-FB18667C9195Q39307013-69B28184-5766-49BC-AFCC-E22BE5C44DF1Q39554319-65C9FF2C-EBC8-4DAF-918A-1FF113DF037FQ39884524-760A3FB2-3FFC-4C4B-A429-E023A3E251F4Q41614877-507DC780-5432-4306-9AE2-211213857E6FQ41616758-A0F34679-1E4B-4700-B941-8A46928526D8Q41708765-B02F2907-2588-492F-B1FB-E8D7B3FDE2EFQ42160986-DC9FA114-62B9-4FFA-9015-5BD10DFA1C2BQ42423159-57E1541B-C783-408B-8BC4-678429173CA3Q42669180-06088907-ABD7-40C5-ACCF-152B0780C75EQ46559488-982FA7E2-552E-4F69-B610-4848D99DBB58Q46582003-70B4B709-288C-4731-80F9-35E1C58A173EQ47988485-A12AB734-DC9B-46A4-8D1B-B08B0EF84DA7Q49564034-F20B249A-73C7-4732-89EE-74C5842B2E1EQ53079996-FC988F7D-6964-4E50-A5A7-8443157CDCA9
P2860
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Identification of a biomarker ...... ation therapy in rectal cancer
@ast
Identification of a biomarker ...... ation therapy in rectal cancer
@en
type
label
Identification of a biomarker ...... ation therapy in rectal cancer
@ast
Identification of a biomarker ...... ation therapy in rectal cancer
@en
prefLabel
Identification of a biomarker ...... ation therapy in rectal cancer
@ast
Identification of a biomarker ...... ation therapy in rectal cancer
@en
P2093
P2860
P1433
P1476
Identification of a biomarker ...... ation therapy in rectal cancer
@en
P2093
Carlos Pastor
David D Smith
Jorge Marcet
Julio Garcia-Aguilar
Peter Cataldo
Robert D Madoff
Zhenbin Chen
P2860
P304
486-92; discussion 492-3
P356
10.1097/SLA.0B013E31822B8CFA
P407
P577
2011-09-01T00:00:00Z